Open to Accrual

Studies that are open to accrual

A5377: Tri-specific Antibody

ACTG A5377:
A Phase I, First-in-Human, Ascending Dose Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants with HIV

Treatment Category:  Treatment Naïve and Treatment Experienced

A5370: Anti-PD-1 Antibody in HIV-1

ACTG A5370: Anti-PD-1 Antibody (Cemiplimab) in Persons Living with HIV (PLWH) on Suppressive cART

Treatment Category: Treatment-experienced

A5369: p24CE Vaccine Study

ACTG A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy

Treatment Category:  Treatment Experienced

Study Description
A5369 is a study that will evaluate the safety and effectiveness of a new vaccine in HIV- infected persons. This vaccine, which is called a therapeutic or treatment vaccine, is not meant to prevent HIV infection but rather to improve how the immune system responds to HIV infection.   

A5345: HIV Rebound & Control Biomarkers

Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control during an Intensively Monitored Antiretroviral Pause (IMAP)

Treatment Category: 

Treatment Experienced

Subscribe to RSS - Open to Accrual